Major depressive disorder (MDD) is the most recurrent mental illness globally, affecting approximately 5% of adults. Furthermore, according to the National Institute of Mental Health (NIMH) of the U.S., calculating an actual schizophrenia prevalence rate is challenging because of this illness's underdiagnosis. Still, most current global metrics hover between 0.33% and 0.75%. Machine-learning scientists use data from diverse sources to analyze, classify, or predict to improve the psychiatric attention, diagnosis, and treatment of MDD, schizophrenia, and other psychiatric conditions. Motor activity data are gaining popularity in mental illness diagnosis assistance because they are a cost-effective and noninvasive method. In the knowledge discovery in databases (KDD) framework, a model to classify depressive and schizophrenic patients from healthy controls is constructed using accelerometer data. Taking advantage of the multiple sleep disorders caused by mental disorders, the main objective is to increase the model's accuracy by employing only data from night-time activity. To compare the classification between the stages of the day and improve the accuracy of the classification, the total activity signal was cut into hourly time lapses and then grouped into subdatasets depending on the phases of the day: morning (06:00-11:59), afternoon (12:00-17:59), evening (18:00-23:59), and night (00:00-05:59). Random forest classifier (RFC) is the algorithm proposed for multiclass classification, and it uses accuracy, recall, precision, the Matthews correlation coefficient, and F1 score to measure its efficiency. The best model was night-featured data and RFC, with 98% accuracy for the classification of three classes. The effectiveness of this experiment leads to less monitoring time for patients, reducing stress and anxiety, producing more efficient models, using wearables, and increasing the amount of data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318635 | PMC |
http://dx.doi.org/10.3390/healthcare10071256 | DOI Listing |
Med Health Care Philos
January 2025
Université de Genève, Genève, Switzerland.
This paper seeks to determine the extent to which individuals with borderline personality disorders can be held morally responsible for a particular subset of their actions: disproportionate anger, aggressions and displays of temper. The rationale for focusing on these aspects lies in their widespread acknowledgment in the literature and their plausible primary association with blame directed at BPD patients. BPD individuals are indeed typically perceived as "difficult patients" (Sulzer 2015:82; Bodner et al.
View Article and Find Full Text PDFZh Nevrol Psikhiatr Im S S Korsakova
December 2024
Mental Health Research Centre, Moscow, Russia.
Objective: Identification of therapeutic targets in the treatment of adolescent depression with attenuated symptoms of schizophrenia and assessment of the effectiveness of therapeutic interventions.
Material And Methods: One hundred and twenty-three patients (mean age 19.6±2.
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Central State Medical Academy, Moscow, Russia.
Objective: To study the features of the clinical picture and diagnosis of Parkinson's disease (PD) in patients with schizophrenia spectrum disorders (SSD).
Material And Methods: The analysis of databases of four psychoneurological dispensaries in Moscow with the allocation of groups of patients with diagnoses of SSD (F20-F25 according to ICD-10) was carried out. Among these groups, a targeted search for patients with an established diagnosis of PD (G20) was conducted.
Int Clin Psychopharmacol
December 2024
Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences.
Current treatments for schizophrenia encounter resistance, limited efficacy, and limiting complications, necessitating novel approaches. The effects of saffron on negative symptoms were investigated as it has shown neuroprotective and antipsychotic properties. Fifty-six clinically stable chronic schizophrenic outpatients were equally assigned to saffron 15 mg q12hr or placebo groups while continuing risperidone.
View Article and Find Full Text PDFArch Psychiatr Nurs
December 2024
Clinical Neuroscience Laboratory (NICE), REGNE Research Laboratory, Faculty of Medicine and pharmacy, Ibn Zohr University, Agadir, Morocco.
Background: Medication non-adherence in schizophrenia is a major cause of relapse and hospitalization, presenting a significant challenge for clinicians. This study was conducted to estimate the prevalence of medication non-adherence and identify the impact of depression, as well as other factors, on medication adherence in individuals with schizophrenia.
Methods: This was a cross-sectional study conducted among individuals with schizophrenia, both outpatients and inpatients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!